Avigen is a research orriented firm discovering drugs to accelerate immune cell development.
Avigen has raised $388K in total funding. The most recent round was Seed. The last funding was announced in March 2025.
Avigen's investors include British Business Bank, SFC Capital.
Avigen is headquartered in London, United Kingdom.
Avigen is a research orriented firm discovering drugs to accelerate immune cell development.
Avigen is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Avigen — Funding & Investors." VCBacked, March 31, 2025, https://www.vcbacked.co/company/avigen. Accessed August 15, 2026.
VCBacked. (2025). Avigen — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/avigen
{{cite web |title=Avigen — Funding & Investors |url=https://www.vcbacked.co/company/avigen |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated